Cytokinetics (CYTK) Stock Price
Cytokinetics Price
Cytokinetics (CYTK) Stock | ISIN US23282W6057 | WKN A1W1KK. The current Cytokinetics stock price is 67.56 USD (2026). Revenue is 121.08 M USD. Net income is -755.35 M USD. The P/E ratio is -10.02. Market capitalization is 8.26 B USD. Cytokinetics operates in the Health sector.
Cytokinetics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Cytokinetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cytokinetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cytokinetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Cytokinetics Price |
|---|
Cytokinetics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Cytokinetics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Cytokinetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cytokinetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cytokinetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Cytokinetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cytokinetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Cytokinetics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Cytokinetics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Cytokinetics business model & stock analysis
Cytokinetics SWOT Analysis
Strengths
1. Innovative Research and Development: Cytokinetics Inc is known for its strong commitment to developing breakthrough therapies for patients with severe diseases.
2. Robust Pipeline: The company has a diverse and promising pipeline of potential drug candidates, targeting various indications including cardiovascular and neuromuscular diseases.
3. Strategic Partnerships: Cytokinetics has formed strategic collaborations with renowned pharmaceutical companies, enhancing its capabilities and resources in advancing drug development.
Weaknesses
1. Limited Product Portfolio: The company heavily relies on the success of its drug candidates, with a limited number of approved products currently available.
2. Dependency on Key Partnerships: Cytokinetics relies on collaborations with partners for funding, expertise, and market access, which introduces a level of dependency and risk.
3. Regulatory Challenges: Like any pharmaceutical company, Cytokinetics faces regulatory hurdles and uncertainty, which can significantly impact the approval and market viability of its drug candidates.
Opportunities
1. Growing Demand for Innovative Therapies: The increasing prevalence of cardiovascular and neuromuscular diseases presents an immense opportunity for Cytokinetics to address unmet medical needs with its R&D efforts.
2. Expansion into New Geographies: The company can explore new markets and expand its global footprint, potentially reaching a larger patient population and generating additional revenue streams.
3. Advancements in Technology: Emerging technologies like gene therapy and precision medicine provide opportunities for Cytokinetics to leverage scientific breakthroughs and develop novel treatment solutions.
Threats
1. Intense Market Competition: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies working on similar therapies, posing a threat to Cytokinetics' market share.
2. Clinical Trial Setbacks: The failure of clinical trials or unexpected safety concerns can result in setbacks and delays, impacting both the company's reputation and financial performance.
3. Pricing and Reimbursement Pressures: Cytokinetics may face challenges in pricing its products competitively and navigating reimbursement processes, which can affect market penetration and profitability.
Cytokinetics Segments
Cytokinetics Revenue by Segment (1/3)
3 Years
5 Years
Max
Details
Cytokinetics Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Cytokinetics Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Cytokinetics Eulerpool Fair Value
Cytokinetics historical P/E ratio, EBIT multiple, and P/S ratio
Cytokinetics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Cytokinetics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Cytokinetics Earnings Estimates
Cytokinetics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | -1.69USD | 8.79 MUSD | 2026 Q1 |
| 3/4/2026 | -1.49USD | 7.05 MUSD | 2025 Q4 |
| 2/25/2026 | -1.49USD | 7.05 MUSD | 2025 Q4 |
| 2/24/2026 | -1.49USD | 7.05 MUSD | 2025 Q4 |
| 5/2/2024 | -1.04USD | 1.58 MUSD | 2024 Q1 |
| 2/28/2024 | -0.99USD | 11.31 MUSD | 2023 Q4 |
| 8/2/2023 | -1.13USD | 4.08 MUSD | 2023 Q2 |
| 5/2/2023 | -1USD | 23.88 MUSD | 2023 Q1 |
| 2/22/2023 | -1.24USD | 8.66 MUSD | 2022 Q4 |
| 11/3/2022 | -1.19USD | 3 MUSD | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Cytokinetics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Cytokinetics shareholder structure
| % | Name |
|---|---|
14.39755% | |
11.29976% | |
9.78039% | |
6.82031% | |
6.40249% | |
5.21246% | |
2.98544% | |
2.48541% | |
2.44924% | |
2.43334% |
Cytokinetics Executives and Management Board
Mr. Robert Blum
(61)President, Chief Executive Officer, Director · since 1998
Mr. Sung Lee
(54)Chief Financial Officer, Executive Vice President
Dr. Fady Malik
(61)Executive Vice President - Research and Development
Mr. Andrew Callos
(56)Executive Vice President, Chief Commercial Officer
Dr. John Henderson
(80)Independent Chairman of the Board
Cytokinetics Supply Chain
Frequently asked questions about Cytokinetics
The business model of Cytokinetics Inc is focused on the discovery and development of novel muscle activators as potential treatments for debilitating diseases. Cytokinetics utilizes its expertise in muscle biology to develop small molecule drug candidates that target muscle function and address diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and hypertrophic cardiomyopathy (HCM). By designing innovative therapies that aim to improve muscle performance, Cytokinetics aims to provide hope for patients suffering from these conditions and enhance their overall quality of life through its scientific research and drug development efforts.
Cytokinetics stock
Cytokinetics Peer Group
Cytokinetics Ticker
Cytokinetics FIGI
All fundamentals and in-depth analysis of Cytokinetics
Our stock analysis for Cytokinetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytokinetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.